LGVN ▼ -3.1% - Longeveron Inc.
$LGVN LGVNR - Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
26-OCT-2026 09:15 AM ET
Share this post
More filings for $LGVN
LGVN ▼ -1.1% - Longeveron Inc.Sep 30, 2026LGVN ▼ -2.6% - Longeveron Inc.Sep 16, 2026LGVN ▲ +2.9% - Longeveron Inc.Sep 3, 2026LGVN - Longeveron Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 13, 2026LGVN - Longeveron Inc. - SEC Filing Update (10-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 10, 2026
View full $LGVN filing history →💬 Comments
Loading comments…
Leave a comment